CoChat
Sign Up
Cited by 126

The DOI matches its Crossref record.

A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems

Shahdadi Sardo, Hossein, Saremnejad, Farinaz, Bagheri, Sara, Akhgari, Abbas, Afrasiabi Garekani, Hadi, Sadeghi, Fatemeh·2019·International Journal of Pharmaceutics
DOI 10.1016/j.ijpharm.2019.01.022
Open this paper in CoChat — free account

Abstract

Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as rapid onset of action and reduction of the dosage of the drug as well as minimization of harmful side effects. 5-aminosalicylic acid (5-ASA) is a drug of choice in the treatment of inflammatory bowel disease and colitis. For the efficient delivery of this drug, it is vital to prevent 5-ASA release in the upper part of the gastrointestinal tract and to promote its release in the proximal colon. Different approaches including chemical manipulation of drug molecule for production of prodrugs or modification of drug delivery systems using pH-dependent, time-dependent and/or bacterially biodegradable materials have been tried to optimize 5-ASA delivery to the colon. In the current review, the different strategies utilized in the design and development of an oral colonic delivery dosage form of 5-ASA are presented and discussed.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2019.01.022

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 141

  1. Abdu-allah, 2016, 5-Aminosalyclic acid (5-ASA): a unique anti-inflammatory salicylate, Med. Chem. (Los. Angeles), 06, 306, 10.4172/2161-0444.1000361 · DOI
  2. Ahmed, 2005, Effect of simulated gastrointestinal conditions on drug release from pectin/ethylcellulose as film coating for drug delivery to the colon, Drug Dev. Ind. Pharm., 31, 465, 10.1080/03639040500214704 · DOI
  3. Akhgari, 2005, Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery, Int. J. Pharm., 305, 22, 10.1016/j.ijpharm.2005.08.025 · DOI
  4. Akhgari, 2006, Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets, Int. J. Pharm., 320, 137, 10.1016/j.ijpharm.2006.05.011 · DOI
  5. Akhgari, 2013, Combination of Pectin and Eudargit RS and Eudragit RL in the matrix of pellets prepared by extrusion-spheronization for possible colonic delivery of 5-amino salicylic acid, Jundishapur J. Nat. Pharm. Prod., 8, 86
  6. Atyabi, 2004, Preparation of ethylcellulose coated gelatin microspheres as a multiparticulate colonic delivery system for 5-aminosalicilic acid, Iran. J. Pharm. Res., 3, 81
  7. Babazadeh, 2007, Application of 2-hydroxyethyl methacrylate polymers in controlled release of 5-aminosalicylic acid as a colon-specific drug, J. Polym. Res., 14, 207, 10.1007/s10965-007-9099-5 · DOI
  8. Bantel, 2000, Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis, Am. J. Gastroenterol., 95, 3452, 10.1111/j.1572-0241.2000.03360.x · DOI
  9. Bautzová, 2012, Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis, Eur. J. Pharm. Biopharm., 81, 379, 10.1016/j.ejpb.2012.02.011 · DOI
  10. Bharti, 2018, Controlled drug release behavior of 5-aminosalicylic acid using polyacrylamide grafted oatmeal (OAT-g-PAM): a pH-sensitive drug carrier, Polym. Bull.
  11. Bostan, 2013, Controlled release of 5-aminosalicylicacid from chitosan based pH and temperature sensitive hydrogels, Int. J. Biol. Macromol., 52, 177, 10.1016/j.ijbiomac.2012.09.018 · DOI
  12. Bruce, 2005, Properties of hot-melt extruded tablet formulations for the colonic delivery of 5-aminosalicylic acid, Eur. J. Pharm. Biopharm., 59, 85, 10.1016/j.ejpb.2004.06.007 · DOI
  13. Canevari, 2009, Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery, Int. J. Pharm., 368, 171, 10.1016/j.ijpharm.2008.09.058 · DOI
  14. Cesar, 2018, New mesalamine polymeric conjugate for controlled release: preparation, characterization and biodistribution study, Eur. J. Pharm. Sci., 111, 57, 10.1016/j.ejps.2017.09.037 · DOI
  15. Chen, 2018, Starch film-coated microparticles for oral colon-specific drug delivery, Carbohydr. Polym., 191, 242, 10.1016/j.carbpol.2018.03.025 · DOI
  16. Cheng, 2004, Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid, World J. Gastroenterol., 10, 1769, 10.3748/wjg.v10.i12.1769 · DOI
  17. Clerici, 1994, Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery, Dig. Dis. Sci., 39, 2601, 10.1007/BF02087696 · DOI
  18. Coco, 2013, Drug delivery to inflamed colon by nanoparticles: comparison of different strategies, Int. J. Pharm., 440, 3, 10.1016/j.ijpharm.2012.07.017 · DOI · Paper page
  19. Das, 2015, Modified hydroxypropyl methyl cellulose: efficient matrix for controlled release of 5-amino salicylic acid, Int. J. Biol. Macromol., 77, 207, 10.1016/j.ijbiomac.2015.03.015 · DOI
  20. Davaran, 1999, Release of 5-amino salicylic acid from acrylic type polymeric prodrugs designed for colon-specific drug delivery, J. Controlled Release, 58, 279, 10.1016/S0168-3659(98)00167-9 · DOI
  21. Davaran, 2001, Synthesis and characterization of methacrylic derivatives of 5-amino salicylic acid with pH-sensitive swelling properties, AAPS PharmSciTech, 2, 1, 10.1208/pt020429 · DOI
  22. Dehghan, 2013, Assessment of isomalt for colon-specific delivery and its comparison with lactulose, AAPS PharmSciTech, 14, 53, 10.1208/s12249-012-9886-0 · DOI
  23. Déo, 2011, Development of mesalazine pellets coated with methacrylic-derived polymer, Brazilian J. Pharm. Sci., 47, 103
  24. Desreumaux, 2006, Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence, Aliment. Pharmacol. Ther., 24, 2, 10.1111/j.1365-2036.2006.03069.x · DOI
  25. Dey, 2017, Colon targeted drug release studies of 5-ASA using a novel pH sensitive polyacrylic acid grafted barley, Polym. Bull., 74, 3431, 10.1007/s00289-016-1898-6 · DOI
  26. Dhaneshwar, 2009, Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease, Eur. J. Med. Chem., 44, 3922, 10.1016/j.ejmech.2009.04.018 · DOI
  27. Di Mario, 2006, Use of mesalazine in diverticular disease, J. Clin. Gastroenterol., 40, 155, 10.1097/01.mcg.0000225509.98041.4b · DOI
  28. Di Pretoro, 2010, Extrusion-spheronisation of highly loaded 5-ASA multiparticulate dosage forms, Int. J. Pharm., 402, 153, 10.1016/j.ijpharm.2010.10.003 · DOI
  29. Duan, 2016, Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon, Colloids Surf. B Biointerfaces, 1, 510, 10.1016/j.colsurfb.2016.05.038 · DOI
  30. Duan, 2017, Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis, Int. J. Pharm., 516, 214, 10.1016/j.ijpharm.2016.11.036 · DOI
  31. El-Bary, 2012, Influence of some formulation variables on the optimization of pH-dependent, colon-targeted, sustained-release mesalamine microspheres, AAPS PharmSciTech, 13, 75, 10.1208/s12249-011-9721-z · DOI
  32. Eyigor, 2018, β-glucan-based temperature responsive hydrogels for 5-ASA delivery, Carbohydr. Polym., 10.1016/j.carbpol.2018.08.053 · DOI
  33. Freeman, 2012, Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates, Clin. Med. Insights Gastroenterol., 5, 77, 10.4137/CGast.S8673 · DOI
  34. Freire, 2010, Assessment of the in-vivo drug release from pellets film-coated with a dispersion of high amylose starch and ethylcellulose for potential colon delivery, J. Pharm. Pharmacol., 62, 55, 10.1211/jpp.62.01.0005 · DOI
  35. Freire, 2010, Influence of the coating formulation on enzymatic digestibility and drug release from 5-aminosalicylic acid pellets coated with mixtures of high-amylose starch and Surelease® intended for colon-specific drug delivery, Drug Dev. Ind. Pharm., 36, 161, 10.3109/03639040903124617 · DOI
  36. Fude, 2007, Preparation and in vitro evaluation of pH, time-based and enzyme-degradable pellets for colonic drug delivery, Drug Dev. Ind. Pharm., 33, 999, 10.1080/03639040601150393 · DOI
  37. Ghanam, 2011, Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release, Int. J. Pharm., 409, 9, 10.1016/j.ijpharm.2011.02.016 · DOI
  38. Gionchetti, 2003, Standard treatment of ulcerative colitis, Dig. Dis., 21, 157, 10.1159/000073247 · DOI
  39. Gohel, 2008, Design of a potential colonic drug delivery system of mesalamine, Pharm. Dev. Technol., 13, 447, 10.1080/10837450802088679 · DOI
  40. Goyanes, 2015, Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations, Int. J. Pharm., 484, 103, 10.1016/j.ijpharm.2015.02.051 · DOI
  41. Günter, 2018, Preparation and release characteristics of mesalazine loaded calcium pectin-silica gel beads based on callus cultures pectins for colon-targeted drug delivery, Int. J. Biol. Macromol., 10.1016/j.ijbiomac.2018.07.078 · DOI
  42. Gupta, 2001, A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables, Int. J. Pharm., 213, 93, 10.1016/S0378-5173(00)00650-5 · DOI
  43. Hartzell, 2013, In vitro digestion and fermentation of 5-formyl-aminosailcylate-inulin: a potential prodrug of 5-aminosalicylic acid, Bioact. Carbohydr. Diet. Fibre, 2, 8, 10.1016/j.bcdf.2013.08.001 · DOI
  44. Hens, 2017, Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities, Int. J. Pharm., 519, 79, 10.1016/j.ijpharm.2016.11.063 · DOI
  45. Hong, 2017, pH-sensitive mesalazine carrier for colon-targeted drug delivery: a two-fold composition of mesalazine with a clay and alginate, Macromol. Res., 25, 1145, 10.1007/s13233-017-5150-5 · DOI
  46. Hu, 2012, A novel preparation method for 5-aminosalicylic acid loaded eudragit S100 nanoparticles, Int. J. Mol. Sci., 13, 6454, 10.3390/ijms13056454 · DOI
  47. Hua, 2015, Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine Nanotechnology, Biol. Med., 11, 1117
  48. Iwao, 2018, Inflamed site-specific drug delivery system based on the interaction of human serum albumin nanoparticles with myeloperoxidase in a murine model of experimental colitis, Eur. J. Pharm. Biopharm., 125, 141, 10.1016/j.ejpb.2018.01.016 · DOI
  49. Jain, 2011, Factorial design-based development of measlamine microspheres for colonic delivery, Biomatter, 1, 182, 10.4161/biom.18461 · DOI
  50. Jin, 2016, A novel pH – enzyme-dependent mesalamine colon-specific delivery system, Drug Des. Dev. Ther., 10, 2021
  51. Jornada, 2016, The prodrug approach: a successful tool for improving drug solubility, Molecules, 21
  52. Joshi, 2005, Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity, Free Radic. Res., 39, 1163, 10.1080/10715760500177880 · DOI
  53. Jung, 1998, Synthesis and evaluation of 5-aminosalicyl-glycine as a potential colon-specific prodrug of 5-aminosalicylic acid, Arch. Pharm. Res., 21, 174, 10.1007/BF02974024 · DOI
  54. Jung, 2000, Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid, J. Pharm. Sci., 89, 594, 10.1002/(SICI)1520-6017(200005)89:5<594::AID-JPS5>3.0.CO;2-8 · DOI
  55. Jung, 2003, Synthesis and properties of 5-aminosalicyl-taurine as a colon- specific prodrug of 5-aminosalicylic acid, Arch. Pharm. Res., 26, 264, 10.1007/BF02976953 · DOI
  56. Jung, 2006, Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis, Eur. J. Pharm. Sci., 28, 26, 10.1016/j.ejps.2005.12.005 · DOI
  57. Kandula, 2016, Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases, Int. Immunopharmacol., 40, 443, 10.1016/j.intimp.2016.09.013 · DOI
  58. Karewicz, 2011, New bilayer-coated microbead system for controlled release of 5-aminosalicylic acid, Polym. Bull., 66, 433, 10.1007/s00289-010-0370-2 · DOI
  59. Karrout, 2009, Novel polymeric film coatings for colon targeting: drug release from coated pellets, Eur. J. Pharm. Sci., 37, 427, 10.1016/j.ejps.2009.03.014 · DOI
  60. Karrout, 2010, Peas starch-based film coatings for site-specific drug delivery to the colon, J. Appl. Polym. Sci., 119, 1176, 10.1002/app.32802 · DOI
  61. Karrout, 2015, In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy, J. Controlled Release, 197, 121, 10.1016/j.jconrel.2014.11.006 · DOI
  62. Khan, 1999, A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers: I. Manipulation of drug release using Eudragit® L100–55 and Eudragit® S100 combinations, J. Controlled Release, 58, 215, 10.1016/S0168-3659(98)00151-5 · DOI
  63. Kim, 2008, Synthesis and properties of N, N ′-Bis(5-aminosalicyl)-L-cystine as a colon-specific deliverer of 5-aminosalicylic acid and cystine, Drug Deliv., 15, 37, 10.1080/10717540701828806 · DOI
  64. Korbely, 2012, Effects of processing on the release profiles of matrix systems containing 5-aminosalicylic acid, AAPS PharmSciTech, 13, 1341, 10.1208/s12249-012-9861-9 · DOI
  65. Krenzlin, 2011, Non-coated multiparticulate matrix systems for colon targeting, Drug Dev. Ind. Pharm., 37, 1150, 10.3109/03639045.2011.562214 · DOI
  66. Lamprecht, 2001, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm. Res., 18, 788, 10.1023/A:1011032328064 · DOI · Paper page
  67. Liu, 2012, Preparation and evaluation of pectin-based colon-specific pulsatile capsule in vitro and in vivo, Arch. Pharm. Res., 35, 1927, 10.1007/s12272-012-1109-4 · DOI
  68. Loftus, 2004, Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis, Aliment. Pharmacol. Ther., 19, 179, 10.1111/j.0269-2813.2004.01827.x · DOI
  69. Long, 2010, Preparation and in vitro evaluation of carboxymethyl konjac glucomannan coated 5-aminosalicylic acid tablets for colonic delivery, Adv. Mater. Res., 152–153, 1712, 10.4028/www.scientific.net/AMR.152-153.1712 · DOI
  70. Mahkam, 2007, New pH-sensitive glycopolymers for colon-specific drug delivery, Drug Deliv., 14, 147, 10.1080/10717540601067745 · DOI
  71. Mahkam, 2010, Novel pH-sensitive hydrogels for colon-specific drug delivery, Drug Deliv., 17, 158, 10.3109/10717541003604908 · DOI
  72. Mahkam, 2006, Synthesis and characterization of acrylic type hydrogels containing azo derivatives of 5-amino salicylic acid for colon-specific drug delivery, Inflammopharmacology, 14, 72, 10.1007/s10787-006-1428-5 · DOI
  73. Malviya, 2018, Synthesis of Aloevera/Acrylonitrile based Nanoparticles for targeted drug delivery of 5-Aminosalicylic acid, Int. J. Biol. Macromol., 106, 930, 10.1016/j.ijbiomac.2017.08.085 · DOI
  74. Mignani, 2013, Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview, Adv. Drug Deliv. Rev., 65, 1316, 10.1016/j.addr.2013.01.001 · DOI
  75. Milojevic, 1996, Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets, J. Controlled Release, 38, 75, 10.1016/0168-3659(95)00112-3 · DOI
  76. Mladenovska, 2007, 5-ASA loaded chitosan-Ca-alginate microparticles: preparation and physicochemical characterization, Int. J. Pharm., 345, 59, 10.1016/j.ijpharm.2007.05.059 · DOI
  77. Mladenovska, 2007, Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles, Int. J. Pharm., 342, 124, 10.1016/j.ijpharm.2007.05.028 · DOI
  78. Mohanty, 2015, Multiparticulate drug delivery system for colon targeting, Int. J. Pharm. Pharm. Sci., 7, 433
  79. Moulari, 2008, The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis, Biomaterials, 29, 4554, 10.1016/j.biomaterials.2008.08.009 · DOI
  80. Mura, 2011, In vitro study of N-succinyl chitosan for targeted delivery of 5-aminosalicylic acid to colon, Carbohydr. Polym., 85, 578, 10.1016/j.carbpol.2011.03.017 · DOI
  81. Mura, 2011, N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats, Int. J. Pharm., 416, 145
  82. Mura, 2012, Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery, Colloids Surf. B Biointerfaces, 94, 199, 10.1016/j.colsurfb.2012.01.030 · DOI
  83. Nam, 2016, Dextran-5-(4-ethoxycarbonylphenylazo)salicylic acid ester, a polymeric colon-specific prodrug releasing 5-aminosalicylic acid and benzocaine, ameliorates TNBS-induced rat colitis, J. Drug Target., 24, 468, 10.3109/1061186X.2015.1087528 · DOI
  84. Neufeld, 2015, Designing a biocompatible hydrogel for the delivery of mesalamine, Int. J. Pharm., 491, 170, 10.1016/j.ijpharm.2015.06.026 · DOI
  85. Nguyen, 2012, Novel mesalamine-loaded beads in tablets for delayed release of drug to the colon, Pharm. Dev. Technol., 17, 73, 10.3109/10837450.2010.516436 · DOI
  86. Nielsen, 2007, Drug Insight: aminosalicylates for the treatment of IBD, Nat. Clin. Pract. Gastroenterol. Hepatol., 4, 160, 10.1038/ncpgasthep0696 · DOI
  87. Nunthanid, 2008, Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose, Eur. J. Pharm. Biopharm., 68, 253, 10.1016/j.ejpb.2007.05.017 · DOI
  88. Omwancha, 2013, Chitosan as a pore former in coated beads for colon specific drug delivery of 5-ASA, Int. J. Pharm., 441, 343, 10.1016/j.ijpharm.2012.11.022 · DOI
  89. Osman, 2017, Novel levan and pNIPA temperature sensitive hydrogels for 5-ASA controlled release, Carbohydr. Polym., 165, 61, 10.1016/j.carbpol.2017.01.097 · DOI
  90. Parmar, 2018, Formulation and optimization of enteric coated bilayer tablets of mesalamine by RSM: in vitro – in vivo investigations and roentogenographic study, J. Drug Deliv. Sci. Technol., 44, 388, 10.1016/j.jddst.2018.01.008 · DOI
  91. Patel, 2009, Design, development and optimization of a novel time and pH-dependent colon targeted drug delivery system, Pharm. Dev. Technol., 14, 62, 10.1080/10837450802409412 · DOI
  92. Patole, 2018, Mesalamine-loaded alginate microspheres filled in enteric coated HPMC capsules for local treatment of ulcerative colitis: in vitro and in vivo characterization, J. Pharm. Investig., 48, 257, 10.1007/s40005-017-0304-1 · DOI
  93. Pereira, 2018, Carcinoembryonic antigen-targeted nanoparticles potentiate the delivery of anticancer drugs to colorectal cancer cells, Int. J. Pharm., 549, 397, 10.1016/j.ijpharm.2018.08.016 · DOI
  94. Pertuit, 2007, 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease, J. Controlled Release, 123, 211, 10.1016/j.jconrel.2007.08.008 · DOI
  95. Popova, 2018, Polymer-coated mesoporous silica nanoparticles for controlled release of the prodrug sulfasalazine, J. Drug Deliv. Sci. Technol., 44, 415, 10.1016/j.jddst.2018.01.020 · DOI
  96. Priyam, 2018, Enhanced solubility and self-assembly of amphiphilic sulfasalazine-PEG-OMe (S-PEG) conjugate into core-shell nanostructures useful for colonic drug delivery, Colloids Surf. A Physicochem. Eng. Asp., 547, 157, 10.1016/j.colsurfa.2018.03.048 · DOI
  97. Qin, 2017, Drug self-delivery systems for cancer therapy, Biomaterials, 112, 234, 10.1016/j.biomaterials.2016.10.016 · DOI · Paper page
  98. Quinteros, 2010, Design of a colonic delivery system based on cationic polymethacrylate (Eudragit E100)-mesalamine complexes, Drug Deliv., 17, 208, 10.3109/10717541003667806 · DOI
  99. Qureshi, 2005, Mesalamine delivery systems: do they really make much difference?, Adv. Drug Deliv. Rev., 57, 281, 10.1016/j.addr.2004.08.008 · DOI
  100. Ribeiro, 2014, Pectin-coated chitosan-LDH bionanocomposite beads as potential systems for colon-targeted drug delivery, Int. J. Pharm., 463, 1, 10.1016/j.ijpharm.2013.12.035 · DOI
  101. Rudolph, 2001, A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis, Eur. J. Pharm. Biopharm., 51, 183, 10.1016/S0939-6411(01)00134-5 · DOI
  102. Saboktakin, 2007, Modification of carboxymethyl starch as nano carriers for oral drug delivery, Nat. Sci., 5, 30
  103. Saboktakin, 2010, Synthesis and characterization of superparamagnetic chitosan-dextran sulfate hydrogels as nano carriers for colon-specific drug delivery, Carbohydr. Polym., 81, 372, 10.1016/j.carbpol.2010.02.034 · DOI
  104. Saboktakin, 2010, Synthesis and characterization of chitosan hydrogels containing 5-aminosalicylic acid nanopendents for colon: specific drug delivery, J. Pharm. Sci., 99, 4955, 10.1002/jps.22218 · DOI
  105. Salahuddin, 2013, Drug release behavior and antitumor efficiency of 5-ASA loaded chitosan-layered silicate nanocomposites, J. Inorg. Organomet. Polym. Mater., 23, 1078, 10.1007/s10904-013-9890-1 · DOI
  106. Sandborn, 2008, Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?, J. Clin. Gastroenterol., 42, 338, 10.1097/MCG.0b013e3181595b56 · DOI
  107. Sandoval, 1997, Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine, Gastroenterology, 113, 1480, 10.1053/gast.1997.v113.pm9352850 · DOI
  108. Sawarkar, 2015, In vivo evaluation of 5-ASA colon-specific tablets using experimental-induced colitis rat animal model, AAPS PharmSciTech, 16, 1445, 10.1208/s12249-015-0331-z · DOI
  109. Schellekens, 2008, Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings, J. Controlled Release, 132, 91, 10.1016/j.jconrel.2008.08.008 · DOI
  110. Sen, 2010, Microwave initiated synthesis of polyacrylamide grafted guar gum (GG-g-PAM)—characterizations and application as matrix for controlled release of 5-amino salicylic acid, Int. J. Biol. Macromol., 47, 164, 10.1016/j.ijbiomac.2010.05.004 · DOI
  111. Siew, 2004, Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro, Int. J. Pharm., 273, 129, 10.1016/j.ijpharm.2003.12.015 · DOI
  112. Singh, 2018, Carboxymethyl cellulose-rosin gum hybrid nanoparticles: an efficient drug carrier, Int. J. Biol. Macromol., 112, 390, 10.1016/j.ijbiomac.2018.01.184 · DOI
  113. Sinha, 2003, Microbially triggered drug delivery to the colon, Eur. J. Pharm. Sci., 18, 3, 10.1016/S0928-0987(02)00221-X · DOI
  114. Sousa, 2014, On the colonic bacterial metabolism of Azo-bonded prodrugs of 5-aminosalicylic acid, J. Pharm. Sci., 103, 3171, 10.1002/jps.24103 · DOI
  115. Sreelatha, 2013, Colon targeted drug delivery–a review on primary and novel approaches, J. Glob. Trends Pharm., 4, 1174
  116. Sriamornsak, 2003, Composite film-coated tablets intended for colon-specific delivery of 5-aminosalicylic acid: using deesterified pectin, Pharm. Dev. Technol., 8, 311, 10.1081/PDT-120022159 · DOI
  117. Steed, 1997, The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (“TIME CLOCK®” system), J. Controlled Release, 49, 115, 10.1016/S0168-3659(97)00062-X · DOI
  118. Tang, 2018, Mesalazine/hydroxypropyl-β-cyclodextrin/chitosan nanoparticles with sustained release and enhanced anti-inflammation activity, Carbohydr. Polym., 198, 418, 10.1016/j.carbpol.2018.06.106 · DOI
  119. Tang, 2017, 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice, Mol. Med. Rep., 15, 1117, 10.3892/mmr.2017.6153 · DOI
  120. Tawfeek, 2017, Colonic delivery of indometacin loaded PGA-co-PDL microparticles coated with Eudragit L100–55 from fast disintegrating tablets, Int. J. Pharm., 531, 80, 10.1016/j.ijpharm.2017.08.069 · DOI
  121. Tian, 2016, Construction of pH-responsive and up-conversion luminescent NaYF 4:Yb3+/Er3+ @SiO2 @PMAA nanocomposite for colon targeted drug delivery, Sci. Rep., 6, 1
  122. Tozaki, 2002, Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats, J. Controlled Release, 82, 51, 10.1016/S0168-3659(02)00084-6 · DOI
  123. Trombino, 2011, Synthesis of pro-prodrugs l-lysine based for 5-aminosalicylic acid and 6-mercaptopurine colon specific release, Int. J. Pharm., 420, 290, 10.1016/j.ijpharm.2011.09.001 · DOI
  124. Tuǧcu-Demiröz, 2004, In-vitro and in-vivo evaluation of mesalazine-guar gum matrix tablets for colonic drug delivery, J. Drug Target., 12, 105, 10.1080/10611860410001693751 · DOI
  125. Tuǧcu-Demiröz, 2007, Evaluation of alginate based mesalazine tablets for intestinal drug delivery, Eur. J. Pharm. Biopharm., 67, 491, 10.1016/j.ejpb.2007.03.003 · DOI
  126. Turkoglu, 2002, In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery, Eur. J. Pharm. Biopharm., 53, 65, 10.1016/S0939-6411(01)00225-9 · DOI
  127. van Langenberg, 2010, The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience, J. Crohn’s Colitis, 4, 413, 10.1016/j.crohns.2010.01.004 · DOI
  128. Vemula, 2009, Different approaches to design and evaluation of colon specific drug delivery systems, Int. J. Pharm. Technol., 1, 1
  129. Wang, 2016, Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis, Int. J. Pharm., 515, 176, 10.1016/j.ijpharm.2016.10.002 · DOI
  130. Wang, 2009, A novel, potential microflora-activated carrier for a colon-specific drug delivery system and its characteristics, Ind. Eng. Chem. Res., 48, 5276, 10.1021/ie801295y · DOI
  131. Wei, 2010, Chitosan/Kollicoat SR 30D film-coated pellets of aminosalicylates for colonic drug delivery, J. Pharm. Sci., 99, 186, 10.1002/jps.21810 · DOI
  132. Williams, 2011, Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease, Therap. Adv. Gastroenterol., 4, 237, 10.1177/1756283X11405250 · DOI
  133. Wilson, 2005, Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets, Int. J. Pharm., 300, 89, 10.1016/j.ijpharm.2005.05.010 · DOI
  134. Xiao, 2018, The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system, Int. J. Pharm., 552, 328, 10.1016/j.ijpharm.2018.10.011 · DOI
  135. Xu, 2014, Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid, Int. J. Pharm., 468, 165, 10.1016/j.ijpharm.2014.04.040 · DOI
  136. Yan, 2018, Colon-targeting mutual prodrugs of 5-aminosalicylic acid and butyrate for the treatment of ulcerative colitis, RSC Adv., 8, 2561, 10.1039/C7RA13011B · DOI
  137. Ye, 2015, Mesalazine preparations for the treatment of ulcerative colitis: are all created equal?, World J. Gastrointest. Pharmacol. Ther., 6, 137, 10.4292/wjgpt.v6.i4.137 · DOI
  138. Yokoe, 2003, Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model, J. Controlled Release, 86, 305, 10.1016/S0168-3659(02)00424-8 · DOI
  139. Zhang, 2016, Melt-Extruded Eudragit® FS-based granules for colonic drug delivery, AAPS PharmSciTech, 17, 56, 10.1208/s12249-015-0357-2 · DOI
  140. Zou, 2005, Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates, World J. Gastroenterol., 11, 7457, 10.3748/wjg.v11.i47.7457 · DOI
  141. Zou, 2005, Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specific delivery systems, Eur. J. Pharm. Biopharm., 59, 155, 10.1016/j.ejpb.2004.06.004 · DOI

Cited by

Sorted by citations

Metadata

Authors
Shahdadi Sardo, H., Saremnejad, F., Bagheri, S., Akhgari, A., Afrasiabi Garekani, H., & Sadeghi, F.
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2019-03
Volume
558
Pages
367-379
ISSN
0378-5173
DOI
10.1016/j.ijpharm.2019.01.022
Cited by
126
References
0
Language
en
Update notices
erratum (2022-11-25)
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review